Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
ADVERSE DRUG INTERACTIONS : a handbook for prescribers
| ADVERSE DRUG INTERACTIONS : a handbook for prescribers |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | [Place of publication not identified], : CRC Press, 2017 |
| Descrizione fisica | 1 online resource (1,214 pages) |
| Disciplina | 615.7/045 |
| Soggetto topico |
Drugs - Side effects
Drug interactions |
| ISBN |
0-429-58633-7
0-429-16002-X 1-4822-3622-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover -- Half Title -- Title Page -- Copyright Page -- Table of Contents -- Acknowledgments -- Abbreviations -- Preface -- Easy Reference Guide to Drugs -- Introduction -- Drug Metabolism and Elimination -- Individual Variability of Adverse Drug Interactions -- Pathological States That Are Associated with Increased Risk of Adverse Drug Interactions -- Special Populations at Higher Risk of Adverse Drug Interactions -- Specific Clinical Problems -- Editors -- Contributors -- Part 1: Drugs Acting on the Cardiovascular System -- Part 2: Drugs Acting on the Central Nervous System -- Part 3: Anticancer and Immunomodulating Drugs -- Part 4: Anticoagulants -- Part 5: Antidiabetic Drugs -- Part 6: Other Endocrine Drugs -- Part 7: Analgesics -- Part 8: Musculoskeletal Drugs -- Part 9: Anesthetic Drugs -- Part 10: Drugs to Treat Infections -- Part 11: Drugs Acting on the Gastrointestinal Tract -- Part 12: Respiratory Drugs -- Part 13: Metabolic Drugs -- Part 14: Obstetrics and Gynecology -- Part 15: Drugs Used to Treat the Urinary System -- Part 16: Drugs of Abuse -- Part 17: Miscellaneous -- Part 18: Over-the-Counter/Online Drugs and Remedies -- Appendix A: Factors Associated with Drug Effects -- Appendix B: Factors Associated with Interactions -- Appendix C: Foods Implicated in Potentially Severe Interactions -- Appendix D: Clinical Drug Development -- Appendix E: Assessments of Manifestations of DDIs -- Appendix F: Triptan Sensations -- Appendix G: Assessment of Severity of Liver Disease -- Appendix H: Prescribing Guidelines for Elderly Patients -- Appendix I: Factors Affecting Efficacy of Anti-Infective Agents -- Appendix J: Assessments of Obesity. |
| Record Nr. | UNINA-9910154926203321 |
| [Place of publication not identified], : CRC Press, 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiepileptic drug interactions : a clinical guide / / P.N. Patsalos
| Antiepileptic drug interactions : a clinical guide / / P.N. Patsalos |
| Autore | Patsalos P. N |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | New York, : Springer, 2013 |
| Descrizione fisica | 1 online resource (463 p.) |
| Disciplina | 615.7045 |
| Soggetto topico |
Anticonvulsants
Drug interactions |
| ISBN |
1-283-93329-2
1-4471-2434-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. I. Drug interactions between AEDs -- pt. II. Drug interactions between AEDs and non-AED drugs : interactions affecting AEDs -- pt. III. Drug interactions between AEDs and non-AED drugs : interactions affected by AEDs. |
| Record Nr. | UNINA-9910438018603321 |
Patsalos P. N
|
||
| New York, : Springer, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiseizure medication interactions : a clinical guide / / Philip N. Patsalos
| Antiseizure medication interactions : a clinical guide / / Philip N. Patsalos |
| Autore | Patsalos Philip N. |
| Edizione | [4th ed.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer International Publishing, , [2022] |
| Descrizione fisica | 1 online resource (327 pages) |
| Disciplina | 615.7045 |
| Soggetto topico |
Drug interactions
Drug interactions - Data processing Anticonvulsius Interaccions dels medicaments |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-82790-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910522937103321 |
|
Patsalos Philip N.
|
||
| Cham, Switzerland : , : Springer International Publishing, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
| Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (506 p.) |
| Disciplina | 615.704 |
| Altri autori (Persone) |
VazRoy J
KlabundeThomas |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
| Record Nr. | UNINA-9910145982103321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
| Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (506 p.) |
| Disciplina | 615.704 |
| Altri autori (Persone) |
VazRoy J
KlabundeThomas |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
| ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
| Record Nr. | UNINA-9910830632603321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antitargets : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
| Antitargets : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (506 p.) |
| Disciplina | 615.704 |
| Altri autori (Persone) |
VazRoy J
KlabundeThomas |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
| ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
| Record Nr. | UNINA-9910877316903321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antitargets and drug safety / / edited by Lásló Urbán, Vinod F. Patel, and Roy J. Vaz
| Antitargets and drug safety / / edited by Lásló Urbán, Vinod F. Patel, and Roy J. Vaz |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , [2015] |
| Descrizione fisica | 1 online resource (1266 p.) |
| Disciplina | 615.19 |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships Drug-Related Side Effects and Adverse Reactions Protein Kinase Inhibitors - adverse effects Pharmacovigilance |
| ISBN |
3-527-67364-4
3-527-67366-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. General concept for target-based safety assessment -- section 2. Hepatic side effects -- section 3. Cardiovascular side effects -- section 4. Kinase antitargets -- section 5. Examples of clinical translation. |
| Record Nr. | UNINA-9910132261703321 |
| Weinheim, Germany : , : Wiley-VCH, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antitargets and drug safety / / edited by Lásló Urbán, Vinod F. Patel, and Roy J. Vaz
| Antitargets and drug safety / / edited by Lásló Urbán, Vinod F. Patel, and Roy J. Vaz |
| Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , [2015] |
| Descrizione fisica | 1 online resource (1266 p.) |
| Disciplina | 615.19 |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships Drug-Related Side Effects and Adverse Reactions Protein Kinase Inhibitors - adverse effects Pharmacovigilance |
| ISBN |
3-527-67364-4
3-527-67366-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. General concept for target-based safety assessment -- section 2. Hepatic side effects -- section 3. Cardiovascular side effects -- section 4. Kinase antitargets -- section 5. Examples of clinical translation. |
| Record Nr. | UNINA-9910823349403321 |
| Weinheim, Germany : , : Wiley-VCH, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applications of Mass Spectrometry in Microbiology : From Strain Characterization to Rapid Screening for Antibiotic Resistance / / edited by Plamen Demirev, Todd R. Sandrin
| Applications of Mass Spectrometry in Microbiology : From Strain Characterization to Rapid Screening for Antibiotic Resistance / / edited by Plamen Demirev, Todd R. Sandrin |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 |
| Descrizione fisica | 1 online resource (336 p.) |
| Disciplina | 540 |
| Soggetto topico |
Mass spectrometry
Microbiology Epidemiology Drug interactions Mass Spectrometry Applied Microbiology Drug Resistance |
| ISBN | 3-319-26070-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- SECTION I. METHODOLOGY AND TECHNIQUES.- Methods and instrumentation in mass spectrometry for the differentiation of closely related microorganisms.- Sample preparation methods for the rapid MS analysis of microorganisms.- Advantages offered by proteomic strategies for rapid biodetection.- Bottom Up Proteomics Methods for Strain-Level Typing and Identification of Bacteria.- Maximizing the taxonomic resolution of MALDI-TOF-MS-based approaches to bacterial characterization: From culture conditions through data analysis -- SECTION II. SUB-SPECIES DISCRIMINATION.- Modulation of the Discriminatory Power of MALDI-TOF MS Profiling for Distinguishing between Closely Related Bacterial Strains.- Discriminatory Power of MALDI-TOF Mass Spectrometry for Phylogenetically Closely Related Microbial Strains.- MALDI-TOF MS as a novel tool for dereplication and characterization of microbiota in bacterial diversity studies.- Bacterial Identification at the Serovar level by Top-down Mass Spectrometry -- SECTION III. DRUG RESISTANCE MONITORING AND ASSAYS.- Rapid profiling of human pathogenic bacteria and antibiotic resistance employing specific tryptic peptides as biomarkers.- Detection of β-lactamases and their activity using MALDI-TOF MS.- Stable-isotope based strategies for rapid determination of drug resistance by mass spectrometry. |
| Record Nr. | UNINA-9910254053303321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Dangerous drug interactions
| Dangerous drug interactions |
| Pubbl/distr/stampa | [Rockville, Md.] : , : Department of Health & Human Services, Substance Abuse and Mental Health Services Administration |
| Descrizione fisica | 1 online resource (1 unnumbered page) : illustrations |
| Collana |
Rx pain medications: know the options, get the facts
SMA |
| Soggetto topico |
Drug interactions
Opioids - Administration Drugs - Prescribing - Management Pain - Treatment - Management Pain medicine |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910716900603321 |
| [Rockville, Md.] : , : Department of Health & Human Services, Substance Abuse and Mental Health Services Administration | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
